Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
(1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/7/454 |
| _version_ | 1827733377004863488 |
|---|---|
| author | Alberto Alvarado-Miranda Fernando Ulises Lara-Medina Wendy R. Muñoz-Montaño Juan W. Zinser-Sierra Paula Anel Cabrera Galeana Cynthia Villarreal Garza Daniel Sanchez Benitez Jesús Alberto Limón Rodríguez Claudia Haydee Arce Salinas Alberto Guijosa Oscar Arrieta |
| author_facet | Alberto Alvarado-Miranda Fernando Ulises Lara-Medina Wendy R. Muñoz-Montaño Juan W. Zinser-Sierra Paula Anel Cabrera Galeana Cynthia Villarreal Garza Daniel Sanchez Benitez Jesús Alberto Limón Rodríguez Claudia Haydee Arce Salinas Alberto Guijosa Oscar Arrieta |
| author_sort | Alberto Alvarado-Miranda |
| collection | DOAJ |
| description | (1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We performed a retrospective study to confirm the efficacy and expand the safety data for capecitabine plus AI (a combination henceforth named XELIA) for this indication. (2) We conducted a single-center retrospective cohort study of 163 hormone receptor-positive metastatic breast cancer patients who received either the XELIA regimen, capecitabine, or an aromatase inhibitor (AI) as single agents in first-line treatment. The primary endpoint was progression-free survival, and the secondary endpoints were overall survival, best objective response, and toxicity incidence. (3) Results: the median progression-free survival for patients receiving XELIA, AI, and capecitabine was 29.37 months (20.91 to 37.84; 95% CI), 20.04 months (7.29 to 32.80; 95% CI) and 10.48 (8.69 to 12.28; 95% CI), respectively. The overall response rate was higher in the XELIA group (29.5%) than in the AI (14.3%) and capecitabine (9.1%) groups. However, the differences in overall survival were not statistically significant. Apart from hand–foot syndrome, there were no statistically significant differences in adverse events between the groups. (4) Conclusions: this retrospective study suggests that progression-free survival and overall response rates improved with the XELIA regimen compared to use of aromatase inhibitors and capecitabine alone. Combined use demonstrated an adequate safety profile and might represent an advantageous treatment in places where CDK 4/6 is not available. Larger studies and randomized clinical trials are required to confirm the effects shown in our study. |
| first_indexed | 2024-03-11T01:10:32Z |
| format | Article |
| id | doaj.art-41144420c00440e4872eb79005101da1 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T01:10:32Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-41144420c00440e4872eb79005101da12023-11-18T18:55:25ZengMDPI AGCurrent Oncology1198-00521718-77292023-06-013076097611010.3390/curroncol30070454Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast CancerAlberto Alvarado-Miranda0Fernando Ulises Lara-Medina1Wendy R. Muñoz-Montaño2Juan W. Zinser-Sierra3Paula Anel Cabrera Galeana4Cynthia Villarreal Garza5Daniel Sanchez Benitez6Jesús Alberto Limón Rodríguez7Claudia Haydee Arce Salinas8Alberto Guijosa9Oscar Arrieta10Breast Tumors Unit, Instituto Nacional de Cancerología, Mexico City 14080, MexicoBreast Tumors Unit, Instituto Nacional de Cancerología, Mexico City 14080, MexicoBreast Tumors Unit, Instituto Nacional de Cancerología, Mexico City 14080, MexicoGastrointestinal Oncology Unit, Instituto Nacional de Cancerología, Mexico City 14080, MexicoBreast Tumors Unit, Instituto Nacional de Cancerología, Mexico City 14080, MexicoBreast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnológico de Monterrey, San Pedro Garza García 66278, MexicoBreast Tumors Unit, Instituto Nacional de Cancerología, Mexico City 14080, MexicoGrupo Opción Oncología, Monterrey 64060, MexicoBreast Tumors Unit, Instituto Nacional de Cancerología, Mexico City 14080, MexicoSchool of Medicine, Universidad Panamericana, Mexico City 03920, MexicoThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico(1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We performed a retrospective study to confirm the efficacy and expand the safety data for capecitabine plus AI (a combination henceforth named XELIA) for this indication. (2) We conducted a single-center retrospective cohort study of 163 hormone receptor-positive metastatic breast cancer patients who received either the XELIA regimen, capecitabine, or an aromatase inhibitor (AI) as single agents in first-line treatment. The primary endpoint was progression-free survival, and the secondary endpoints were overall survival, best objective response, and toxicity incidence. (3) Results: the median progression-free survival for patients receiving XELIA, AI, and capecitabine was 29.37 months (20.91 to 37.84; 95% CI), 20.04 months (7.29 to 32.80; 95% CI) and 10.48 (8.69 to 12.28; 95% CI), respectively. The overall response rate was higher in the XELIA group (29.5%) than in the AI (14.3%) and capecitabine (9.1%) groups. However, the differences in overall survival were not statistically significant. Apart from hand–foot syndrome, there were no statistically significant differences in adverse events between the groups. (4) Conclusions: this retrospective study suggests that progression-free survival and overall response rates improved with the XELIA regimen compared to use of aromatase inhibitors and capecitabine alone. Combined use demonstrated an adequate safety profile and might represent an advantageous treatment in places where CDK 4/6 is not available. Larger studies and randomized clinical trials are required to confirm the effects shown in our study.https://www.mdpi.com/1718-7729/30/7/454aromatase inhibitorcapecitabinemetastatic breast cancermetronomic chemotherapycombined therapy |
| spellingShingle | Alberto Alvarado-Miranda Fernando Ulises Lara-Medina Wendy R. Muñoz-Montaño Juan W. Zinser-Sierra Paula Anel Cabrera Galeana Cynthia Villarreal Garza Daniel Sanchez Benitez Jesús Alberto Limón Rodríguez Claudia Haydee Arce Salinas Alberto Guijosa Oscar Arrieta Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Current Oncology aromatase inhibitor capecitabine metastatic breast cancer metronomic chemotherapy combined therapy |
| title | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer |
| title_full | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer |
| title_fullStr | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer |
| title_full_unstemmed | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer |
| title_short | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer |
| title_sort | capecitabine plus aromatase inhibitor as first line therapy for hormone receptor positive her2 negative metastatic breast cancer |
| topic | aromatase inhibitor capecitabine metastatic breast cancer metronomic chemotherapy combined therapy |
| url | https://www.mdpi.com/1718-7729/30/7/454 |
| work_keys_str_mv | AT albertoalvaradomiranda capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT fernandouliseslaramedina capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT wendyrmunozmontano capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT juanwzinsersierra capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT paulaanelcabreragaleana capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT cynthiavillarrealgarza capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT danielsanchezbenitez capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT jesusalbertolimonrodriguez capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT claudiahaydeearcesalinas capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT albertoguijosa capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer AT oscararrieta capecitabineplusaromataseinhibitorasfirstlinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcancer |